Bevacizumab for the treatment of glioblastoma

Expert Review of Neurotherapeutics

Volumn 13, Issue 8, 2013, Pages 937-949

  Chowdhary, Sajeel ^a,b,c   Chamberlain, Marc ^d,e,f  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b FLORIDA HOSPITAL   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

anti angiogenesis; bevacizumab; glioblastoma; high grade glioma; MGMT; VEGF

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CELECOXIB; ENZASTAURIN; FORETINIB; IRINOTECAN; KFN 951; LINIFANIB; LOMUSTINE; NINTEDANIB; PAZOPANIB; REGORAFENIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TIVOZANIB; TREBANANIB; UNCLASSIFIED DRUG; VANDETANIB;

ADJUVANT CHEMORADIOTHERAPY; ANGIOGENESIS; BLOOD TOXICITY; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CRANIOTOMY; DIARRHEA; DRUG COST; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; EPISTAXIS; FATIGUE; GLIOBLASTOMA; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; REOPERATION; REVIEW; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS;

EID: 84882793036     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.827414     Document Type: Review

References (110)

1. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009
2. Cloughesy T, Vredenburgh JJ, Day B et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol. 28(15 Suppl.), Abstract 2008 (2010
3. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253-1259 (2007
4. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007
5. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009
6. Quant E, Norden AD, Drappatz J et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J. Clin. Oncol. 26(15 Suppl.) (2008
7. Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol. 99(2), 237-242 (2010
8. Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J. Clin. Oncol. 26(6), 1012-1013 (2008
9. Gilbert MR, Wang MH, Aldape KD et al. RTOG 0525: A randomized Phase III trial comparing standard adjuvant temozolomide (TMZ) with dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). Neuro-Oncol. 13(Suppl. 3), Abstract 46 (2011
10. Stupp R, Dietrich PY, Ostermann KS et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20, 1375-1382 (2002
11. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26(13), 2192-2197 (2008
12. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005
13. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005
14. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E; Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: Long-Term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien) 148(3), 269-275; discussion 275 (2006
15. Westphal M, Hilt DC, Bortey E et al. A Phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol. 5, 79-88 (2003
16. Vauleon E, Mesbah H, Gedouin D et al. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab]. Bull. Cancer 99, 121-126 (2012
17. Spiegel BM, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: A meta-Analysis. CNS Drugs 21, 775-787 (2007
18. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncol. 7, 369, Abstract 342 (2005
19. Chinnaiyan P, Chowdhary S, Potthast L et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro-Oncol. 14(1), 93-100 (2012
20. Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 359, 492-507 (2008
21. Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncol. 10, 162-170 (2008
22. Sathornsumetee S, Rich JN. Molecularly targeted therapy in neuro-oncology. Handb. Clin. Neurol. 104, 255-278 (2012
23. de Groot JF. High-dose antiangiogenic therapy for glioblastoma: Less may be more? Clin. Cancer Res. 17(19), 6109-6111 (2011
24. Shirai K, Siedow MR, Chakravarti A. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J. Oncol. 2012, 193436 (2012
25. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms. Expert Opin. Ther. Targets 13, 455-468 (2009
26. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971
27. Risau W. Mechanisms of angiogenesis. Nature 386(6626), 671-674 (1997
28. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438(7070), 932-936 (2005
29. Fidler IJ, Ellis LM. Neoplastic angiogenesis -not all blood vessels are created equal. N. Engl. J. Med. 351(3), 215-216 (2004
30. Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin. Oncol. 28(1), 93-105 (2001
31. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69(Suppl. 3), 11-16 (2005
32. Brem S, Cotran R, Folkman J. Tumor angiogenesis: A quantitative method for histologic grading. J. Natl Cancer Inst. 48, 347-356 (1972
33. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat. Rev. Neurosci. 8, 610-622 (2007
34. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82 (2007
35. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004
36. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25, 1539-1544 (2007
37. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006
38. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007
39. Rohr UP, Augustus S, Lasserre SF, Compton P, Huang J. Safety of bevacizumab in patients with metastases to the central nervous system. J. Clin. Oncol. 27(15 Suppl.), Abstract 2007 (2009
40. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncol. 7, 134-153 (2005
41. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004
42. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005
43. Reardon DA, Desjardins A, Peters KB et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J. Neurooncol. 107, 155-164 (2011
44. Desjardins A, Reardon DA, Coan A et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118, 1302-1312 (2011
45. Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin. Med. Insights Oncol. 5, 117-129 (2011
46. Sathornsumetee S, Desjardins A, Vredenburgh JJ et al. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J. Clin. Oncol. 27(15 Suppl.), Abstract 2045 (2009
47. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70, 779-787 (2008
48. Gilbert MR, Wang M, Aldape K et al. RTOG 0625: A Phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). J. Clin Oncol. 27(15 Suppl.), Abstract 2011 (2009
49. Desjardins A, Reardon DA, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res. 14, 7068-7073 (2008
50. Rademaker AW, Renfrow J, Bredel M. A Phase 2 trial of single-Agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297-5305 (2010
51. De Fazio S, Russo E, Ammendola M, Di Paola ED, De Sarro G. Efficacy and safety of bevacizumab in glioblastomas. Curr. Med. Chem. 19, 972-981 (2012
52. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91, 329-336 (2009
53. Hapani S, Wu S. Controversial role of bevacizumab in the development of venous thromboembolic events. J. Clin. Oncol. 29(25), 3490; author reply 3490-3491 (2011
54. Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-Associated toxicites of anti-Angiogenic therapy in patients with brain tumors. Neuro-Oncol. doi:10.1093/neuonc/nor223 (2012
55. Vogelbaum MA, Jost S, Aghi MK et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 70(1), 234-243; discussion 243-244 (2012
56. Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-Agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297-5305 (2010
57. Selfridge JM. Timing of bevacizumab in recurrent glioblastoma. SNO Annual Scientific Meeting Washington DC, USA November 2012
58. Clark AJ, Butowski NA, Chang SM et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J. Neurosurg. 114(6), 1609-1616 (2011
59. Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol. 106(1), 121-125 (2012
60. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011
61. Narayana A, Gruber D, Kunnakkat S et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 116(2), 341-345 (2011
62. Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res. 17(12), 4119-4124 (2011
63. Chinot OL. AVAglio preliminary data presentation. SNO Annual Scientific Meeting 2012. Preliminary AVAglio data presented by Chinot revealing a significant increase in PFS so far in the arm that received BEV plus SOC Washington DC, USA November 2012
64. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358(11), 1129-1136 (2008
65. Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing bevacizumab in patients with glioblastoma: An ethical analysis. Oncologist 16(10), 1435-1439 (2011
66. Najafi M, Soltanian-Zadeh H, Jafari-Khouzani K, Scarpace L, Mikkelsen T. Prediction of glioblastoma multiform response to bevacizumab treatment using multi-parametric MRI. PLoS One 7(1), e29945 (2012
67. Clark AJ, Lamborn KR, Butowski NA et al. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery 70(2), 361-370 (2012
68. Brandes AA, Tosoni A, Franceschi E et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status. J. Clin. Oncol. 27, 1275-1279 (2009
69. Goldlust SA, Cavaliere R, Newton HB et al. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J. Neurooncol. 107(2), 407-411 (2012
70. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: An emerging paradigm of anti-VEGF therapy. Expert Opin. Biol. Ther. 8, 541-553 (2008
71. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17, 2572-2578 (1999
72. Ananthnarayan S, Bahng J, Roring J et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J. Neurooncol. 88(3), 339-347 (2008
73. Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: Perceptions and evidence. Curr. Neurol. Neurosci. Rep. 11(3), 305-312 (2011
74. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 28(11), 1963-1972 (2010
75. Greenfield JP, Jin DK, Young LM et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 64(5), 819-826; discussion 826-827 (2009
76. Schmidt NO, Westphal M, Hagel C et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 84, 10-18 (1999
77. Salmaggi A, Eoli M, Frigerio S et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J. Neurooncol. 62, 297-303 (2003
78. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clin. Cancer Res. 9, 3369-3375 (2003
79. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3́-kinase and distinct from that induced by hypoxia. Cancer Res. 60, 5879-5886 (2000
80. Winkler F, Kozin SV, Tong R et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004
81. Gorski DH, Beckert MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999
82. Rosell R, de Las PR, Balana C et al. Translational research in glioblastoma multi-forme: Molecular criteria for patient selection. Future Oncol. 4, 219-228 (2008
83. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 63, 236-241 (2003
84. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010
85. Wen PY, Prados M, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients with progressive glioblastoma (GB). J. Clin. Oncol. 28(15 Suppl.), Abstract 2006 (2010
86. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28(7), 1168-1174 (2010
87. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18(4), 708-715 (2000
88. Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 54(1), 31-38 (2001
89. Kesari S, Schiff D, Henson JW et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncol. 10(3), 300-308 (2008
90. Pan E, Yu D, Yue B et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J. Neurooncol. 110(1), 111-118 (2012
91. Kreisl TN, Smith P, Sul J et al. Continuous daily sunitinib for recurrent glioblastoma. J. Neurooncol. 111(1), 41-48 (2013
92. Lee EQ, Kuhn J, Lamborn KR et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncol. 14(12), 1511-1518 (2012
93. de Groot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J. Clin. Oncol. 29(19), 2689-2695 (2011
94. Drappatz J, Norden AD, Wong ET et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 85-90 (2010
95. Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A Phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro-Oncol. 14(12), 1519-1526 (2012
96. Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-Targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncol. 12(8), 855-861 (2010
97. Muhic A, Poulsen HS, Sorensen M, Grunnet K, Lassen U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J. Neurooncol. 111(2), 205-212 (2013
98. Doi T, Ohtsu A, Fuse N et al. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71(1), 227-235 (2013
99. Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res. 72(5), 1103-1115 (2012
100. Nakamura K, Taguchi E, Miura T et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 66(18), 9134-9142 (2006
101. Hedgethorne K, Huang PH. Foretinib. c-Met and VEGFR-2 inhibitor, oncolytic. Drugs Fut. 35(11), 893-901 (2010
102. Albert DH, Tapang P, Magoc TJ et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 5(4), 995-1006 (2006
103. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat. Rev. Cancer 10(7), 505-514 (2010
104. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer 8(8), 604-617 (2008
105. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93(3), 178-193 (2001
106. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005
107. Neufeld G, Kessler O. The semaphorins: Versatile regulators of tumour progression and tumour angiogenesis. Nat. Rev. Cancer 8(8), 632-645 (2008
108. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 358(19), 2039-2049 (2008
109. Grothey A, Cutsem EV, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863), 303-312 (2013
110. Idbaih A, Ducray F, Sierra DR, Hoang-Xuan K, Delattre JY. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: Growth factor receptors and angiogenesis inhibitors. Oncologist 13, 978-992 (2008